Pre-emptive antiviral therapy for CMV infection following allogeneic stem cell transplantation is an effective strategy for preventing CMV disease. This entails the logistic difficulty of daily intravenous therapy with ganciclovir or foscarnet to clinically asymtomatic patients. Cidofovir (CDV) is effective against CMV in vitro and has the practical advantage of weekly administration. However, there are limited data on the pre-emptive use of CDV in CMV infections. We carried out a pilot study exploring the efficacy and toxicity of CDV as primary pre-emptive therapy for CMV infections monitored by PCR-based assays. CDV was used at 5 mg/kg with probenecid and hydration, weekly for a maximum of 4 weeks, followed by fortnightly maintenance treatment. Four patients were treated with CDV and two of them responded. Both the non-responders developed CMV disease. There was no renal toxicity noted in any of the patients, but three patients had severe vomiting and one developed uveitis, which precluded maintenance treatment in the two responders. Following failure of CDV, foscarnet was effective in controlling the CMV infection in both patients, although the infection recurred in both. Thus, larger randomised studies are required before CDV can be recommended as a primary pre-emptive therapy for post-transplant CMV infections. Bone Marrow Transplantation (2001) 28, 879-881.
Pre-emptive antiviral therapy for CMV infection following allogeneic stem cell transplant (SCT) is currently more widely practised than the prophylactic approach. 1 Use of ganciclovir (GCV) or foscarnet (FSC) for this purpose has been shown to be equally effective. 2 We have experienced a low incidence of CMV disease using pre-emptive GCV, but delivering daily intravenous drugs to clinically well outpatients poses a logistic burden both to the transplant unit and to the patients and their families. Cidofovir (CDV) has been effective in treating CMV retinitis in patients with HIV disease and is an attractive choice as pre-emptive therapy post SCT since it requires only weekly administration in a day-care setting. The retrospective survey on CDV therapy by Ljungman et al 3 reported on the use of CDV for CMV infection or disease. They identified 26 patients treated pre-emptively with a response rate of 58%. However, the role of CDV as primary pre-emptive therapy still remains unclear.
In view of this, we present the preliminary data from our pilot study exploring the efficacy and toxicity of CDV as primary pre-emptive therapy for CMV infections in allogeneic SCTs.
Case reports
Four patients have been treated with pre-emptive CDV when two consecutive PCR assays were positive. Two patients (UPN 1 and 2) were screened by a qualitative assay (Roche, Amplicor) 4 and the other two patients (UPN 3 and 4) were monitored by a quantitative assay (Cobas Amplicor, Roche, Lewes, UK), 5 the threshold for detection being CMV genome copies exceeding 400/ml of plasma. CDV (Pharmacia and Upjohn, Little Chalfont, UK) was administered at 5 mg/kg weekly for a maximum of 4 weeks or until two negative PCR assays, whichever was earlier.
The protocol included maintenance treatment fortnightly for two additional doses. Probenecid 2 g was given 3 h before CDV treatment followed by 1 g 4 and 8 h later. Patients received anti-emetics and intravenous hydration and were monitored for renal function and electrolyte abnormalities. Ocular examination was carried out before each dose and the urine was tested for protein.
Side-effects and outcome of the four patients treated in this study are detailed in Table 1 . One developed bilateral anterior uveitis 10 days after the fourth course of treatment. There was no renal toxicity, but three patients experienced moderate to severe vomiting related to probenecid. UPN 1 and UPN 4 could not receive maintenance CDV due to gastro-intestinal and ocular toxicities, respectively. There was no significant alteration in the blood count. All patients were receiving oral cyclosporin A during CDV therapy.
Only two of the four patients responded after four doses of CDV. When studied by the non-quantitative assay (UPN 1), the first negative PCR assay was obtained after four ALL ϭ acute lymphoblastic leukaemia; AML ϭ acute myeloid leukaemia; cam ϭ Campath; CDV ϭ cidofovir; CML ϭ chronic myeloid leukaemia; CMV ϭ cytomegalovirus; cyclo ϭ cyclophosphamide; D ϭ donor; F ϭ female; flu ϭ fludarabine; GI ϭ gastro-intestinal; GVHD ϭ graft-versus-host disease; M ϭ male; mel ϭ melphalan; MM ϭ multiple myeloma; MSD ϭ matched sibling donor; MUD ϭ matched unrelated donor; R ϭ recipient; TBI ϭ total body irradiation; TCD ϭ T cell depleted.
doses of CDV. The quantitative assay in UPN 3 ( Figure 1 ) demonstrated a decrease in the viral DNA load after the second dose of CDV, although reduction below the detection limit was achieved only after the fourth dose. Both the patients (UPN 2 and 4) with treatment failure developed CMV pneumonia. UPN 2 died of fulminant CMV pneumonia 2 weeks after a response to foscarnet therapy for 4 weeks. UPN 4 had a progressive increase in the CMV copies and was switched to GCV after three doses of CDV. She went on to develop CMV pneumonia on GCV and improved on addition of FSC. Sequencing of the UL97 gene of CMV from this patient was carried out using a PCR-based assay as previously described. 6 This revealed a mutation at codon 500. 
Discussion
There are limited data on the use of CDV in allogeneic SCT recipients. CDV is supposed to have a broad therapeutic spectrum against a wide range of DNA viruses. Acyclovirand foscarnet-resistant HSV strains have been shown to be susceptible to cidofovir in vitro. 7 There are some anectodal reports on its use in acyclovir-resistant HSV infections. 7 However, there are fewer reports on the use of CDV for CMV infection. 8, 9 In the survey by Ljungman et al, 3 50% of the patients treated for CMV disease improved, but 34% patients treated pre-emptively apparently failed to respond to CDV. The cause for failure was not cited in this study. All our patients received the scheduled treatment with CDV and this was not precluded by toxicity. No renal toxicity was noted in any of the patients. However, none of the responders could receive maintenance CDV because of gastrointestinal (UPN 1) or ocular (UPN 3) toxicities. Probenecid intolerance and uveitis have been reported in patients treated for AIDSassociated CMV retinitis, 10 but the extent of this problem in SCT recipients is not known.
CDV resistance is generally associated with mutations in UL54 gene and is reported to be time-dependent. 11 De novo resistance to CDV is rare and isolates having resistance to both GCV and CDV may still be sensitive to FSC. 11 This was demonstrated in both the non-responders (UPN 2 and 4) who responded to FSC. The mutation in UL97 gene detected in UPN 4 has not been described previously in association with GCV resistance and its significance is currently unclear.
Thus, although CDV is logistically attractive for the preemptive treatment of CMV infection post-SCT, we would advocate caution. In our view, pilot approaches to preemptive therapy should be guided by quantitative assays, as the trend of CMV DNA load after the first two doses may predict the ultimate response. Foscarnet may be a rational choice for patients failing CDV therapy. The role of CDV as primary pre-emptive therapy should be evaluated in randomised comparative studies before its use can be recommended.
